Model Informed Drug Development Archives

On-Demand Webinar

From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations

SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client &…

CertaraJanuary 3, 2025

Poster

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias

CertaraDecember 12, 2024

Video

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…

CertaraDecember 10, 2024

Publication

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…

CertaraDecember 9, 2024

Press Coverage

Forbes: Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Published: November 27, 2024 Recent decades have seen continuing declines in pharmaceutical R&D productivity. Inflation…

CertaraNovember 27, 2024

Poster

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

CertaraNovember 22, 2024

Poster

Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis.

CertaraNovember 22, 2024

Poster

Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials

CertaraNovember 22, 2024

Poster

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma

CertaraNovember 22, 2024

Poster

A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model

CertaraNovember 22, 2024

Model Informed Drug Development

From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

Forbes: Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis.

Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma

A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model

Newsletter sign up

Quick links

Solutions

Contact